ReviewAntibiotics (Basel, Switzerland)2022
Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Clinical Outcomes of Pandrug-Resistant Versus Carbapenem-Resistant, Colistin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Article
- Comorbidities and mortality in colistin-resistant gram-negative infections among hospitalized patients in Qassim, Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.Journal of clinical medicine · 2025Review
- Intrahospital dissemination of multidrug-resistantInfection prevention in practice · 2025Article
- Prevalence of difficult-to-treat resistance in ESKAPE pathogens in a third level hospital in Mexico.Infection prevention in practice · 2025Article
- Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDRMicroorganisms · 2024Review
- Critical role of growth medium for detecting drug interactions in Gram-negative bacteria that modelmBio · 2024Article
- Article
- Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-PositiveInfection and drug resistance · 2024Article
- Retrospective analysis of Acinetobacter baumannii bacteraemia risk factors, complications and mortality in a tertiary university hospital in Saudi Arabia.Access microbiology · 2024Article
- Structure-Based Optimization of 1,2,4-Triazole-3-Thione Derivatives: Improving Inhibition of NDM-/VIM-Type Metallo-β-Lactamases and Synergistic Activity on Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Antimicrobial Stewardship in the Hospital Setting: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Off-Label Use of Ceftazidime/Avibactam for the Treatment of Pan-Drug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020-2021: a multicenter study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Peptaibol Analogs Show Potent Antibacterial Activity against Multidrug Resistant Opportunistic Pathogens.International journal of molecular sciences · 2023Article
- Evolution of Antibiotic Resistance inJournal of clinical medicine · 2023Article
- Editorial for Special Issue "Antimicrobial Therapy in Intensive Care Unit".Antibiotics (Basel, Switzerland) · 2023Article
- The Role of the Respiratory Microbiome in the Pathogenesis of Aspiration Pneumonia: Implications for Diagnosis and Potential Therapeutic Choices.Antibiotics (Basel, Switzerland) · 2023Review
- Evaluation of In Vitro Activity of Double-Carbapenem Combinations against KPC-2-, OXA-48- and NDM-ProducingAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem resistance in Gram-negative bacteria has come into sight as a serious global threat. Carbapenem-resistant Gram-negative pathogens and their main representatives
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.